Dani Bancroft, Author at Labiotech.eu - Page 4 of 23

About

Former Editor, now flitting back and forth as a freelancer. Originally from London and studied Zoology at the University of Reading, UK. Previous work includes having written for The Spark University Newspaper and the Wellcome Trust.

Articles by Dani Bancroft

vedanta microbiome seventure health capital fund finance jj live biotech

News and Trends 6 Jun 2016

‘Living’ Therapeutics in Boston attract major French Microbiome Money

Health for Life Capital, managed by Seventure Partners, has invested $8M (€7.15M) as part of a $50M financing round completed by Boston-based Vedanta Biosciences. This seems to be a great match between one of the most influential Microbiome investors and one of the most successful Microbiome biotechs. The basis for the financing is a live-bioproduct from […]

June 6, 2016 - 3 minutesmins - By Dani Bancroft

car t cancer immunooncology biotech labiotech refresh georges rawadi

News and Trends 6 Jun 2016

CAR-T: “This is totally different from what everyone else is doing”

And on the topic of CAR-T, Joachim spoke to Georges Rawadi from the Belgium based biotech, Celyad. Having originally been built on research into a cell therapy for cardiology, Celyad started back in 2007. Now Rawadi explained it’s coming to the end of a cycle for the Cardiology programme. So naturally, they asked what next? Well – […]

June 6, 2016 - 2 minutesmins - By Dani Bancroft

MiNa therapeutics rna liver disease biotech

News and Trends 2 Jun 2016

RNA therapy starts first-of-a-kind trial to treat Liver Cancer

MiNA Therapeutics is launching the first saRNA human trial of its kind – OUTREACH for patients with severe liver cancer. MiNA Therapeutics is a London based RNA specialist, developing RNA activation therapeutics that restore normal function to patients’ cells with an initial focus on severe liver cancer. The study is the first-in-human trial of a small activating RNA […]

June 2, 2016 - 2 minutesmins - By Dani Bancroft

gene therapy strimvelis biotech gsk offerele ada scid child

News and Trends 1 Jun 2016

EMA approves Groundbreaking Gene Therapy for Super Rare ‘Bubble Baby’ Disease

GSK, Fondazione Telethon and Ospedale San Raffaele have announced that the EMA has approved Strimvelis for a super rare immunodeficiency disease in Children. Following 20 years of research at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) in Italy, this is the news patients have been waiting for. Strimvelis is the first ex vivo stem cell gene […]

June 1, 2016 - 3 minutesmins - By Dani Bancroft

crispr therapeutics gene editing labiotech refresh philip hemme biotech roger novak

News and Trends 1 Jun 2016

CRISPR Thx’ Founder: “We have over $250M in the bank”

So begins our series of videos documenting our biotech conference premier – Labiotech Refresh. Here Philip spoke with Rodger Novak, the CEO and founder of CRISPR Therapeutics, which is leading the biotech front on Gene Editing in Europe. Having the CEO of CRISPR Therapeutics come and speak at our first event was really exciting for […]

June 1, 2016 - 2 minutesmins - By Dani Bancroft

Springwave spirulina algae microalgae biotech drink hong kong facebook drink algama

News and Trends 31 May 2016

Asian Super investor claims stake in Microalgae Drink Startup

The French startup Algama has received €3.5M investment from the Hong Kong billionaire, Li Ka-shing, known for his stakes in Facebook, Spotify, and Skype. Based on a microalgae brew, Algama’s nutritional drinks product SpringWave is evidently hitting the marketing mark, by making the algae Spirulina a tasty. But there are many other algae-based products which look to compete in this Omega-3 and […]

May 31, 2016 - 2 minutesmins - By Dani Bancroft

ADVERTISEMENT

nasdaq merus biotech ipo closing immunooncology cancer breast ovarian colorectal finance

News and Trends 30 May 2016

Dutch Immuno-Oncology Biotech closes massive IPO on the NASDAQ

The Utrecht based Merus has snagged around $47.3M (€42.5M) in an IPO on the NASDAQ market for its portfolio of antibodies targeting breast and colorectal cancers. Back in April 2015, Merus announced its intention to go public on the Nasdaq, with the goal of raising at least €100M for the rest of the year, but […]

May 30, 2016 - 2 minutesmins - By Dani Bancroft

labiotech refresh startup conference may berlin biotech startup highlights

News and Trends 27 May 2016

So that was Labiotech Refresh! Here are the conference Highlights

So after months of planning our first biotech conference, it’s kind of surreal to think it’s actually over. For now, anyway! Here’s a recap of the day; speakers, panels, audience and the team, as we put together the premier of Labiotech’s Conference series – Labiotech Refresh. Philip and Joachim during the opening speech. It all kicked […]

May 27, 2016 - 5 minutesmins - By Dani Bancroft

virtiuakl biotech cloud lab robert thong industry emerald

News and Trends 23 May 2016

To Be – or Not To Be, a Virtual Biotech?

Many new biotechs start off as virtual companies. But at each stage of development, you always end up asking whether you should stay virtual or build your own in-house wet labs. What are the pros and cons of being virtual? And is there a more pragmatic “semi-virtual” approach? Pros and Cons of being Virtual Biotechs […]

May 23, 2016 - 5 minutesmins - By Dani Bancroft

international green week monsanto gmo bayer farmer protest acquisition offer biotech

News and Trends 23 May 2016

Bayer offers Big Buy out for the infamous Monsanto. Shareholders are not pleased…

Yes, everyone is talking about how Germany’s Pharma giant Bayer has made a $62 billion offer for the infamous chemicals conglomerate Monsanto. And not many like it. Bayer’s products mostly consist of human and veterinary pharmaceuticals, consumer healthcare products, agricultural chemicals, biotechnological products, and high value polymers. Monsanto on the other hand is notorious for its agricultural chemicals, GMOs […]

May 23, 2016 - 3 minutesmins - By Dani Bancroft

abbvie bms empliciti multiple myeloma cancer immunooncology ema

News and Trends 13 May 2016

First and only antibody for Multiple Myeloma approved in EU

Bristol-Myers Squibb and AbbVie have announced that their co-development project for an antibody therapy against Multiple Myeloma has been approved in the EU after a successful Phase III trial. Empliciti (elotuzumab) has been developed for the treatment of multiple myeloma as combination therapy in patients who have received at least one prior therapy, now making it […]

May 13, 2016 - 3 minutesmins - By Dani Bancroft

adenoviral lentiviral cell lines gene therapy cevec aav cap rca free biotech

News and Trends 12 May 2016

German Biotech achieves next step for Gene Therapy production of Viral Vectors

Cologne based Cevec specialises in producing tailor-made recombinant glycoproteins and gene therapy vectors. Now it has announced a breakthrough in their adenoviral vectors used in Gene Therapy. The increasing number of gene therapy-based discovery programs in the biotech and pharma industry is driving a greater need for the scalable production of gene therapy vectors. Vectors are needed […]

May 12, 2016 - 2 minutesmins - By Dani Bancroft

ADVERTISEMENT